Search

Multiresistant Mycobacterium abscessus ulcer treated with photodynamic therapy with methyl-aminolevulinate A new approach to the treatment of nontuberculous mycobacterium skin infections caused by iatrogenic manipulation: photodynamic therapy combined with antibiotics: a pilot study. I Mycobacterium abscessus i is a rapidly growing mycobacterium.1 They are a rare cause of infections with an incidence of 0.2 per 100,000.2 The lungs are the most frequent site of infection. [Extracted from the article]

Eccrine squamous syringometaplasia (ESS) is a skin condition histopathologically characterized by squamous metaplasia of the cuboidal basophilic epithelial cells of the sweat ducts.1 EES has been observed in association with tumors, infections, or inflammatory dermatoses, most frequently in the context of antitumoral treatments with cytotoxic agents and in some isolated cases after the use of non-cytotoxic drugs.1 We report the first case of ESS associated to Natalizumab. Erosive lesions, ulcerations, or recent scars are commonly seen in ESS not related to chemotherapy.1,9 The latency period was longer in this case, possibly because all the drugs that have been associated with squamous syringometaplasia up to now, that are not chemotherapy drugs, have a shorter latency period. On physical examination, the eruption consisted of erythematous violaceous papules with a tendency to ulceration and painful ulcers of up to 2 cm located on the back of the hands (Figure 1). [Extracted from the article]

Methyl aminolevulinate daylight photodynamic therapy (MAL DL‐PDT) is highly efficacious for the treatment of nonhyperkeratotic actinic keratosis (AK), even when partially performed at home. To evaluate the long‐term effectiveness, safety, and patient‐reported outcomes of MAL DL‐PDT performed completely by the patient in real life conditions. An open prospective study was conducted in Spain among patients diagnosed with at least five AK lesions on the face or the scalp. Patients received instruction and information in infographic format to perform MAL DL‐PDT at home. All had been treated with 30% urea daily for 7 days before the day of MAL DL‐PDT. Meteorological conditions on the day of the treatment and adverse effects were recorded. Patients underwent follow‐up, and a second session of home‐based MAL DL‐PDT if deemed necessary, 3, 6, and 12 months after the initial treatment session. The study population consisted of 22 patients (19 men and three women, mean [standard deviation, SD] age, 72.05 [6.96] years). A complete response was observed in 47.7% of AK lesions at 3 months (p < 0.001) and 65.9% (n = 199) at 12 months (p < 0.001). Olsen grade II lesions showed the highest rate of response (76.07% at 12 months). The mean (SD) actinic keratosis area and severity index score decreased significantly from 4.99 (2.43) at baseline to 2.33 (1.01) at 12 months (p = 0.0234). Adverse effects were mild and expected. A majority of patients were "satisfied" or "very satisfied" with the treatment instruction provided (90.9%) and the treatment outcome (72.7%). MAL DL‐PDT can be applied at home like any other topical treatment for AK. Our results indicate good long‐term effectiveness, a high level of patient satisfaction, and no significant side effects. [ABSTRACT FROM AUTHOR]